ClinicalTrials.gg
RecruitingNCT07066657Updated Aug 13, 2026

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

A Phase 1 interventional study of MRG007 and MRG007 and Bevacizumab in Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer and Gastric Cancer, sponsored by ArriVent BioPharma, Inc.. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by ArriVent BioPharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
572
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
16th of 224
572 · median 63
Started
2025
with 12 others
Phase 1
26 of 230
5 open now
Primary completion
2028-03
later than 44 of 60 live
Registered
215th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 16th largest by planned enrollment of the 224 interventional ones that give a count, is one of 13 that started in 2025, is one of 26 in phase 1, reaches primary completion later than 44 of the 60 other live ones, and was the 215th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors
  • Colorectal Cancer
  • Gastric Cancer
  • Pancreatic Cancer

Keywords

  • MRG007
  • Advanced or Metastatic Solid Tumors
  • CDH17
  • ARR-217
  • ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Willing to sign the form and follow the requirements specified in the protocol.
  2. ≥ 3 months.
  3. Tumor specimen available for CDH17 testing, or agree to at baseline.
  4. Patients with and cytologically confirmed advanced or solid tumor who have failed or intolerant to standard therapy, or without alternative standard therapy.
  5. Patients must have at least one according to the (RECIST v1.1).
  6. The score of for performance status is 0 or 1.
  7. Organ functions and coagulation function must meet the basic requirements.
  8. Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion Criteria:

  1. Patients with more than one cancer.
  2. Received CDH17-targeting anti-tumor therapy; received other product, systemic or surgery for major organs within 4 weeks prior to the first dose; received anti-tumor therapy within 3 weeks or within 5 half-lives prior to the first dose, whichever is shorter; received radiotherapy within 2 weeks prior to the first dose; received strong inducers or inhibitors within 2 weeks prior to the first dose or 5 half-lives, whichever is longer; investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose.
  3. ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment
  4. Symptomatic Central nervous system and/or meninges metastasis.
  5. History of severe cardiovascular diseases
  6. Cerebrovascular accident, pulmonary embolism, or deep venous thrombosis within 3 months prior to the first dose, implantable venous infusion port or catheter-related thrombosis, or superficial venous thrombosis
  7. History of previous or combined interstitial pneumonia, current interstitial pneumonia, or suspected interstitial pneumonia that cannot be ruled out through imaging during screening, severe with respiratory failure, severe pulmonary dysfunction, symptomatic bronchospasm, etc.
  8. Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion
  9. Infection of active , active , or
  10. Uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections requiring intravenous anti-infection therapy within 2 weeks prior to the first study treatment
  11. Known allergic reactions to any component of MRG007, or known Grade≥3 allergic reactions to other prior anti-CDH17 (including investigational) or other monoclonal antibody.
  12. Other situations that are not suitable to participate a clinical trial per investigator's judgement
  13. Additional protocol-defined exclusion criteria apply
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
572 participants (estimated)

Study arms

  • Experimental
    MRG007

    Drug: MRG007

  • Experimental
    MRG007 and Bevacizumab

    Drug: MRG007 and Bevacizumab

Interventions

  • DrugMRG007

    MRG007 will be administrated as specified in the protocol.

    Also known as: ARR-217

  • DrugMRG007 and Bevacizumab

    Drug page: Bevacizumab

    MRG007 will be administered as specified in the protocol

    Also known as: ARR-217

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) - Phase Ia

    Time frame: Baseline to Day 21 of the first treatment cycle

  2. Serious Adverse Events (SAEs)

    Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions

    Time frame: Baseline to 30 days after the last dose of study treatment

  3. Treatment-Emergent Adverse Event (TEAE)

    AEs that occur or worsen on or after the first dose of study treatment

    Time frame: Baseline to 30 days after the last dose of study treatment

  4. Treatment-Related Adverse Event

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.

    Time frame: Baseline to 30 days after the last dose of study treatment

  5. Objective Response Rate (ORR) as assessed by investigator - Phase Ib

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

Secondary outcomes

  1. Objective Response Rate (ORR) - Phase Ia

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion (up to 24 months)

  3. Duration of Response (DOR)

    The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.

    Time frame: Baseline to study completion (up to 24 months)

  4. Progression Free Survival (PFS) as assessed by investigator

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  5. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  6. Incidence of anti-drug antibody (ADA)

    The proportion of patients with positive ADA results.

    Time frame: Baseline to 30 days after the last dose.

  7. Incidence of neutralizing antibody (NAb)

    The proportion of patients with positive NAb results.

    Time frame: Baseline to 30 days after the last dose.

  8. Tmax

    Time to reach the maximum blood concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  9. Cmax

    Maximum observed blood concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  10. AUC0-t

    Area under the blood concentration-time curve from time 0 to the time of last quantifiable concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  11. QTc interval

    Serum concentrations of MRG007, TAb, and unconjugated payload and change in QT interval corrected by Fridericia's formula (ΔQTcF) interval.

    Time frame: Baseline to 30 days after the last dose of study treatment

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 32 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 15, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Dec 2030
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066657
Lead sponsor
ArriVent BioPharma, Inc.
Collaborators
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jul 25, 2025
Primary completion
Mar 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 13, 2026

Study contacts

Clinical Trials
Contact
ClinicalTrials.gov@ArriVent.com
(888) 622-2827

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion